A breakthrough in the treatment of a widespread and serious cardiac condition affecting millions of older adults globally is being spearheaded by researchers at the University of Missouri. This development promises a novel therapeutic strategy for aortic valve calcification.

Details of the Groundbreaking Research

In a significant advancement, Dunpeng Cai, an assistant professor at the University of Missouri School of Medicine, has been awarded a prestigious five-year, .8 million R01 grant from the National Institutes of Health. This highly competitive grant will support his crucial investigation into the underlying causes of aortic valve calcification. This progressive ailment is characterized by the gradual hardening and narrowing of the heart's aortic valve, leading to increased cardiac workload and symptoms such as chest discomfort, breathing difficulties, and eventually heart failure.

Professor Cai's current research endeavors are focused on developing what could become the very first pharmaceutical intervention for this debilitating disease. He emphasizes the intricate nature of the condition, stating, "The mechanisms driving aortic valve calcification are extremely complex, making the disease difficult to study. Millions of patients are waiting for a treatment, and that makes this challenge worth pursuing."

Earlier collaborative work with clinicians at University Hospital involved comparing healthy and calcified human aortic valve tissues. During this study, Cai made a pivotal discovery: patients afflicted with aortic valve calcification exhibited elevated levels of DOCK2, a protein instrumental in regulating immune cells, within their aortic valve cells.

The new grant will enable Cai's research team to rigorously evaluate whether the targeted blockade of DOCK2 using a drug compound can effectively slow down or halt the progression of the disease. Cai elaborates on their hypothesis: "If we can show that knocking out DOCK2 with a drug compound in animal models can slow, stop or even reverse the buildup of calcium in the aortic valve, the drug may also work in humans with the disease. What's important to remember is that most proteins can have both a good side and a bad side. Since DOCK2 plays a key role in the immune system, the goal is to target its role in aortic valve calcification without causing unwanted side effects."

Further investigations will involve in vitro studies of aortic valve cells to deepen the understanding of DOCK2's precise contribution to the disease's development. Should this innovative approach yield positive results, Professor Cai intends to collaborate with experts at the Roy Blunt NextGen Precision Health building to advance the promising drug candidate towards clinical trials. He highlights that the cutting-edge research infrastructure at NextGen Precision Health, alongside the Genomics Technology Core at the Bond Life Sciences Center, significantly expedites such groundbreaking discoveries. Cai notes, "At some universities, researchers have to seek out these resources externally. Having world-class research infrastructure right on campus here at Mizzou helps us conduct our research much more efficiently."

This pioneering research by Professor Cai and his team offers a beacon of hope for countless individuals suffering from aortic valve calcification. The meticulous investigation into DOCK2's role and the development of a targeted drug treatment could revolutionize the management of this serious heart condition. The collaborative environment and state-of-the-art facilities at the University of Missouri are clearly fostering an ecosystem ripe for significant medical breakthroughs, ultimately benefiting global public health.